文献速递泌尿生殖与妇科肿瘤放疗

局部晚期宫颈癌放疗靶区排除非受累子宫(EXIT试验):基于现代放疗与影像技术的个体化治疗联合完成性手术

Exclusion of non-Involved uterus from the target volume (EXIT-trial): An individualized treatment for locally advanced cervical cancer using modern radiotherapy and imaging techniques followed by completion surgery.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-05-11

单臂2期EXIT试验纳入21例局部晚期宫颈癌患者,基于MRI将距肿瘤至少12 mm的非受累子宫排除出靶区(EXIT靶区)行放化疗后完成性子宫切除术;

要点

  • 21例局部晚期宫颈癌患者非靶区子宫均病理阴性,EXIT靶区放化疗未残留肿瘤。
  • 15例计划对比显示膀胱、乙状结肠、直肠的Dmean及多个V15Gy–V50Gy剂量指标显著降低。

核心结论

  • 基于MRI将距肿瘤至少12 mm的非肿瘤受累部分子宫排除出靶区,在局部晚期宫颈癌中不增加非靶区子宫残留病变风险,并显著降低周围危及器官的高剂量受照体积。

研究设计与样本

  • 单臂2期研究,共21例局部晚期宫颈癌患者(FIGO I期2例、II期14例、III期3例、IV期2例),勾画标准全子宫靶区与EXIT靶区(排除距肿瘤至少12 mm的非肿瘤受累子宫部分)。
  • 全部患者接受针对EXIT靶区的放化疗,随后行完成性子宫切除术;其中15例患者进行PTV与PTV_EXIT两套治疗计划的剂量学比较。
  • 主要终点为非靶区子宫(NTU)病理无肿瘤受累;次要终点包括靶区缩小对危及器官的剂量学影响、急慢性毒性、总生存(OS)、无局部区域复发生存(LRFS)和无进展生存(PFS)。

主要发现

  • 全部21例患者的非靶区子宫病理均为阴性。
  • 15例计划对比中,膀胱、乙状结肠和直肠的Dmean显著降低;乙状结肠和直肠的V15Gy、膀胱、乙状结肠和直肠的V30Gy、膀胱、肠袋、乙状结肠和直肠的V40Gy与V45Gy、直肠的V50Gy均显著降低。
  • 中位随访54个月(范围7–79个月);急性毒性主要为2级,3级泌尿系毒性占5%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Chemoradiotherapy followed by brachytherapy is the standard of care for locally advanced cervical cancer (LACC). In this study, we postulate that omitting an iconographical unaffected uterus (+12 mm distance from the tumour) from the treatment volume is safe and that no tumour will be found in the non-targeted uterus (NTU) leading to reduction of high-dose volumes of surrounding organs at risk (OARs). MATERIAL AND METHODS: In this single-arm phase 2 study, two sets of target volumes were delineated: one standard-volume (whole uterus) and an EXIT-volume (exclusion of non-tumour-bearing parts of the uterus with a minimum 12 mm margin from the tumour). All patients underwent chemoradiotherapy targeting the EXIT-volume, followed by completion hysterectomy. In 15 patients, a plan comparison between two treatment plans (PTV vs PTV_EXIT) was performed. The primary endpoint was the pathological absence of tumour involvement in the non-targeted uterus (NTU). Secondary endpoints included dosimetric impact of target volume reduction on OARs, acute and chronic toxicity, overall survival (OS), locoregional recurrence-free survival (LRFS), and progression-free survival (PFS). RESULTS: In all 21 (FIGO stage I: 2; II: 14;III: 3; IV: 2) patients the NTU was pathologically negative. Ssignificant reductions in Dmean in bladder, sigmoid and rectum; V15Gy in sigmoid and rectum, V30Gy in bladder, sigmoid and rectum; V40Gy and V45Gy in bladder, bowel bag, sigmoid and rectum; V50Gy in rectum were achieved. Median follow-up was 54 months (range 7-79 months). Acute toxicity was mainly grade 2 and 5 % grade 3 urinary. The 3y- OS, PFS and LRFS were respectively 76,2%, 64,9% and 81 %. CONCLUSION: MRI-based exclusion of the non-tumour-bearing parts of the uterus at a minimum distance of 12 mm from the tumour out of the target volume in LACC can be done without risk of residual disease in the NTU, leading to a significant reduction of the volume of surrounding OARS treated to high doses.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Van Damme A, Tummers P, De Visschere P, et al. Exclusion of non-Involved uterus from the target volume (EXIT-trial): An individualized treatment for locally advanced cervical cancer using modern radiotherapy and imaging techniques followed by completion surgery. Clin Transl Radiat Oncol. 2024. PMID: 38798749. doi:10.1016/j.ctro.2024.100793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。